Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13788578 | 1.00 | ADORA3 (0.53) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL10089198 | 0.82 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL8922587 | 0.82 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL14256082 | 0.81 | ADORA3 (0.50) | ADORA3ADORA1ADORA2A | |
| SCHEMBL12359596 | 0.80 | ADORA3 (0.58) | ADORA3ADORA1ADORA2A | |
| SCHEMBL14072684 | 0.80 | ADORA3 (0.58) | ADORA3ADORA1ADORA2A | |
| SCHEMBL14264202 | 0.80 | ADORA3 (0.76) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL14364574 | 0.80 | ADORA3 (0.58) | ADORA3ADORA1ADORA2A | |
| SCHEMBL19837856 | 0.77 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL2778569 | 0.76 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-12-18 | — | — | US | disclosed |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADENOSINE THERAPEUTICS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA1 4/4885ADORA2A 1/4885 |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADORA2A, ADORA3, ADORA2B | ADORA3 2/4885ADORA1 4/4885ADORA2A 1/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | ADORA3 4/4885ADORA1 10/4885ADORA2A 1/4885 |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | ADORA2A, ADORA3, GLUL | ADORA3 2/4885ADORA1 6/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.